BHFAP vs FRME

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, indicating significant fundamental deterioration. Despite deeply discounted valuation metrics—P/E of 1.32 and Price/Book of 0.15—the company faces declining revenue (YoY -10.10%) and concerning capital structure risks, including high debt/equity of 1.47. The absence of an Altman Z-Score prevents a full distress risk assessment, but weak ROA of 0.73% and negative long-term price performance suggest underlying operational fragility. While the 9.89% dividend yield and recent short-term price rebound offer temporary appeal, these are outweighed by structural challenges and lack of analyst coverage or insider support.

FRME presents as a classic value play with a stable Piotroski F-Score of 4/9, trading at a discount to its Graham Number ($61.18) and slightly below book value (P/B 0.97). While the company maintains a strong track record of earnings beats and a sustainable dividend, it is currently hampered by negative year-over-year revenue (-4.60%) and earnings growth (-10.90%). The valuation attractiveness is offset by bearish insider sentiment and a very weak technical trend, suggesting a period of stagnation or a potential value trap if growth does not pivot.